Drug intelligence / Profile preview

BTX 1303

Development stage: Preclinical
Lead developer: Botanix Pharmaceuticals
Administration: Topical

Overview

BTX 1303 is an investigational topical dermatology drug candidate developed by Botanix Pharmaceuticals for the treatment of psoriasis. It was advanced through preclinical development as part of Botanix’s BTX pipeline of synthetic cannabinoid-based or related dermatologic therapies, with the goal of providing a new mechanism of action and improved topical delivery for inflammatory skin disease; however, detailed public information on its exact active ingredient, molecular target, and formulation has not been disclosed.

Beyond the preview

Go deeper on BTX 1303.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BTX 1303.

Explore the full profile